MB
RVMD icon

MPM BioImpact’s Revolution Medicines RVMD Stock Holding History

MPM BioImpact’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.3M Buy
506,776
+1,104
+0.2% +$111K 3.81% 7
2025
Q4 		$40.3M Buy
505,672
+189,950
+60% +$12.5M 4.61% 6
2025
Q3 		$14.7M Hold
315,722
– – 2.41% 19
2025
Q2 		$11.6M Sell
315,722
-1,361
-0.4% -$52.3K 2.01% 22
2025
Q1 		$11.2M Buy
317,083
+3,266
+1% +$133K 1.93% 19
2024
Q4 		$13.7M Buy
313,817
+22,426
+8% +$1.13M 1.95% 20
2024
Q3 		$13.2M Buy
291,391
+1,995
+0.7% +$86.9K 1.98% 19
2024
Q2 		$11.2M Buy
289,396
+16,179
+6% +$605K 1.75% 19
2024
Q1 		$8.81M Sell
273,217
-191
-0.1% -$5.66K 1.42% 27
2023
Q4 		$7.84M Hold
273,408
– – 1.83% 24
2023
Q3 		$7.57M Hold
273,408
– – 2.02% 18
2023
Q2 		$7.31M Buy
273,408
+26,386
+11% +$647K 1.47% 20
2023
Q1 		$5.35M Buy
247,022
+97,979
+66% +$2.41M 1.39% 20
2022
Q4 		$3.55M Buy
149,043
+3,002
+2% +$63.8K 0.92% 23
2022
Q3 		$2.88M Hold
146,041
– – 0.68% 28
2022
Q2 		$2.85M Hold
146,041
– – 0.79% 28
2022
Q1 		$3.73M Hold
146,041
– – 1% 28
2021
Q4 		$3.68M Sell
146,041
-3,959
-3% -$112K 0.67% 28
2021
Q3 		$4.13M Buy
+150,000
New +$4.37M 0.64% 29

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MPM BioImpact's RVMD Position: Q1 2026 in Review

MPM BioImpact increased its Revolution Medicines (RVMD) stake by 0.22% in Q1 2026, buying an estimated $111K and bringing the position to 506,776 shares worth $49.3M. The position accounts for 3.81% of the portfolio, ranked #7.

MPM BioImpact first reported a position in RVMD in Q3 2021 and has held it in 19 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • MPM BioImpact held 506,776 shares of Revolution Medicines worth $49.3M as of Q1 2026.
  • MPM BioImpact bought 1,104 Revolution Medicines shares in Q1 2026, an estimated $111K.
  • Revolution Medicines made up 3.81% of MPM BioImpact's portfolio in Q1 2026, its #7 holding.
  • MPM BioImpact first reported a position in Revolution Medicines in Q3 2021 and has held it in 19 quarters since.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on MPM BioImpact's 13F filing for Q1 2026, filed 15 May 2026.